Bellerophon Therapeutics (BLPH)
(Delayed Data from OTC)
$0.04 USD
0.00 (0.00%)
Updated Sep 23, 2024 03:46 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Bellerophon Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | NA | 0 | 0 | 0 | 0 |
Cost Of Goods | NA | 0 | 0 | 0 | 0 |
Gross Profit | NA | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 0 | 22 | 20 | 26 | 17 |
Income After Depreciation & Amortization | 0 | -22 | -20 | -26 | -17 |
Non-Operating Income | NA | 0 | 1 | -1 | 2 |
Interest Expense | NA | 0 | 0 | 0 | 0 |
Pretax Income | NA | -22 | -20 | -27 | -15 |
Income Taxes | NA | -2 | -2 | -2 | -2 |
Minority Interest | NA | 0 | 0 | 0 | 0 |
Investment Gains/Losses | NA | 0 | 0 | 0 | 0 |
Other Income/Charges | NA | 0 | 0 | 0 | 0 |
Income From Cont. Operations | NA | -20 | -18 | -25 | -13 |
Extras & Discontinued Operations | NA | 0 | 0 | 0 | 0 |
Net Income (GAAP) | NA | -20 | -18 | -25 | -13 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 0 | -22 | -20 | -26 | -17 |
Depreciation & Amortization (Cash Flow) | NA | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | 0 | -22 | -20 | -26 | -17 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | NA | 9.55 | 9.50 | 7.80 | 4.50 |
Diluted EPS Before Non-Recurring Items | NA | -2.08 | -1.87 | -3.06 | -2.95 |
Diluted Net EPS (GAAP) | NA | -2.08 | -1.87 | -3.17 | -2.95 |
Fiscal Year end for Bellerophon Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | NA | NA | 0.00 | 0.00 |
Cost Of Goods | NA | NA | NA | 0.00 | 0.00 |
Gross Profit | NA | NA | NA | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 2.17 | 5.26 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | -2.17 | -5.26 |
Non-Operating Income | NA | NA | NA | 0.25 | 0.12 |
Interest Expense | NA | NA | NA | 0.00 | 0.00 |
Pretax Income | NA | NA | NA | -1.92 | -5.14 |
Income Taxes | NA | NA | NA | 0.00 | 0.00 |
Minority Interest | NA | NA | NA | 0.00 | 0.00 |
Investment Gains/Losses | NA | NA | NA | 0.00 | 0.00 |
Other Income/Charges | NA | NA | NA | 0.00 | 0.00 |
Income From Cont. Operations | NA | NA | NA | -1.92 | -5.14 |
Extras & Discontinued Operations | NA | NA | NA | 0.00 | 0.00 |
Net Income (GAAP) | NA | NA | NA | -1.92 | -5.14 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | NA | 12.23 | 12.23 |
Diluted EPS Before Non-Recurring Items | NA | NA | NA | -0.16 | -0.42 |
Diluted Net EPS (GAAP) | NA | NA | NA | -0.16 | -0.42 |